340450.KQ GC Genome Corporation Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
03:10
Aug 19
Aug 19
GC Genome expects Japan and US approvals.
GC Genome holds the #1 market share in Korea's NIPT market, generating continuous quarterly profits and holding over 40 billion KRW in net cash. Upcoming catalysts include Japan MHLW certification in September and US FDA submission for its pancreatic cancer screening test.
HIGH
02:21
Aug 19
Aug 19
GC Genome has liquid biopsy catalysts
GC Genome is Korea's NIFTY prenatal screening leader with an estimated 35% market share, profitable operations, and a strong cash position relative to its market cap. Catalysts include possible Japan Ministry of Health approval in September, US colorectal cancer screening clinical results by September-October and potential FDA submission in December. Global peers Guardant Health and Natera show the market opportunity, and Stanley Druckenmiller has a large position in Natera.
HIGH
About 340450.KQ Analyst Coverage
Buzzberg tracks 340450.KQ (GC Genome Corporation) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (50%). 2 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: Noh Young-rae.